Credit Agricole’s BioMarin Pharmaceuticals BMRN Stock Holding History

Credit Agricole’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,400	Closed	-$315K	–	1473
2016 Q3	$315K	Sell	3,400 -18,900	-85%	-$1.78M	﹤0.01%	1396
2016 Q2	$1.74M	Buy	+22,300	New	+$1.9M	0.01%	889

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Credit Agricole's BMRN Position: Q4 2025 in Review

Credit Agricole sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 7,860 shares — an estimated $426K sold.

Credit Agricole first reported a position in BMRN in Q3 2013 and held it in 46 quarters. The position peaked at $15.8M in Q3 2017. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Credit Agricole reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Credit Agricole sold 7,860 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $426K.
Credit Agricole first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 46 quarters.
Credit Agricole's BioMarin Pharmaceuticals position peaked at $15.8M in Q3 2017.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Credit Agricole's 13F filing for Q4 2025, filed 17 Feb 2026.